Dataset Information

COPD-MouseExperiment

ABSTRACT: Smoking of combustible cigarettes has a major impact on human health, so the tobacco industry is developing modified risk tobacco products (MRTP) to reduce this health risk. Using a systems toxicology approach in a model of chronic obstructive pulmonary disease (C57BL/6 mice), we assessed the potential of such a prototype (pMRTP) to reduce health risk. We investigated physiological endpoints in parallel with transcriptomics, lipidomics, and proteomics profiles in mice exposed to conventional cigarette smoke (3R4F) or a pMRTP aerosol for up to 7 months. We also included a cessation group and a switching-to-pMRTP group (after 2 months of 3R4F exposure) in addition to the control (fresh air-exposed) group, to understand the potential risk reduction of switching to pMRTP compared with continuous 3R4F exposure. The present manuscript describes the study design, setup, and implementation, as well as the generation, processing, and quality control analysis of the toxicology and "omics" datasets that are accessible in public repositories for further studies.

OTHER RELATED OMICS DATASETS IN: PXD001369MTBLS143

INSTRUMENT(S): Affymetrix GeneChip(R) HT Scanner, Affymetrix GeneChip Scanner 3000 7G

ORGANISM(S): Mus musculus

SUBMITTER: Stephanie Boue Sam Ansari

PROVIDER: E-MTAB-3150 | ArrayExpress | 2015-01-30

REPOSITORIES: ArrayExpress

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 19

Publications

Comprehensive systems biology analysis of a 7-month cigarette smoke inhalation study in C57BL/6 mice.

Ansari Sam S Baumer Karine K Boué Stéphanie S Dijon Sophie S Dulize Remi R Ekroos Kim K Elamin Ashraf A Foong Clement C Guedj Emmanuel E Hoeng Julia J Ivanov Nikolai V NV Krishnan Subash S Leroy Patrice P Martin Florian F Merg Celine C Peck Michael J MJ Peitsch Manuel C MC Phillips Blaine B Schlage Walter K WK Schneider Thomas T Talikka Marja M Titz Bjoern B Vanscheeuwijck Patrick P Veljkovic Emilija E Vihervaara Terhi T Vuillaume Gregory G Woon Ching Qing CQ

Scientific data 20160105

Smoking of combustible cigarettes has a major impact on human health. Using a systems toxicology approach in a model of chronic obstructive pulmonary disease (C57BL/6 mice), we assessed the health consequences in mice of an aerosol derived from a prototype modified risk tobacco product (pMRTP) as compared to conventional cigarettes. We investigated physiological and histological endpoints in parallel with transcriptomics, lipidomics, and proteomics profiles in mice exposed to a reference cigaret ...[more]

PMID: 26731301

Similar Datasets

Project description:BACKGROUND:Tobacco harm reduction, substituting less harmful tobacco products for combustible cigarettes, is a complementary approach for smokers who would otherwise continue to smoke. The Philip Morris International (PMI) Tobacco Heating System (THS) 2.2 is a novel tobacco product with the potential to reduce the risk of harm in smokers compared to continued smoking of combustible cigarettes. It heats tobacco electrically in a controlled manner, never allowing the temperature to exceed 350°C, thereby preventing the combustion process from taking place and producing substantially lower levels of toxicants while providing nicotine, taste, ritual, and a sensory experience that closely parallels combustible cigarettes. Previous clinical studies have demonstrated reduced exposure to the toxicants (approaching the levels observed after quitting) for smokers who switched to THS 2.2, for three months. For adult smokers who would otherwise continue smoking combustible cigarettes, switching to THS 2.2 may represent an alternative way to reduce the risk of tobacco-related diseases. OBJECTIVE:This study aimed to further substantiate the harm reduction potential of THS 2.2 by demonstrating favorable changes in a set of 8 coprimary endpoints, representative of pathomechanistic pathways (ie, inflammation, oxidative stress, lipid metabolism, respiratory function, and genotoxicity), linked to smoking-related diseases, in smokers switching from combustible cigarettes to THS 2.2. METHODS:This study was a randomized, controlled, two-arm parallel group, multicenter ambulatory US study conducted in healthy adult smokers switching from combustible cigarettes to THS 2.2 compared with smokers continuing to smoke combustible cigarettes for six months. Subjects had a smoking history of at least ten years and did not intend to quit within the next six months. RESULTS:Enrollment started in March 2015 and the trial was completed in September 2016. In total, 984 subjects were randomized (combustible cigarettes, n=483; THS 2.2, n=477), and 803 completed the study. The results are expected to be available in a subsequent publication in 2019. CONCLUSIONS:In this paper, we describe the rationale and design for this clinical study that focused on the evaluation of THS 2.2's potential to reduce the risk of smoking-related diseases compared with that of combustible cigarettes. This study will provide insights regarding favorable changes in biological and functional endpoints informed by effects known to be seen upon smoking cessation. TRIAL REGISTRATION:ClinicalTrials.gov NCT02396381; http://clinicaltrials.gov/ct2/show/NCT02396381 (Archived by WebCite at http://www.webcitation.org/71PCRdagP). REGISTERED REPORT IDENTIFIER:RR1-10.2196/11294.

			Action	DRS
	E-MTAB-3150.idf.txt	Idf
	E-MTAB-3150.processed.1.zip	Processed
	E-MTAB-3150.raw.1.zip	Raw
	E-MTAB-3150.raw.10.zip	Raw
	E-MTAB-3150.raw.11.zip	Raw